[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612877":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":10,"locations":15,"responsibleParty":35,"collaborators":10,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":41,"sex":47,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":10,"studyType":53,"phases":10,"briefSummary":54,"conditions":55,"keywords":59,"overallStatus":18,"whyStopped":10,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"University of Padova","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Eleveld TCI",null,"Patients who received general anesthesia with Eleveld TCI model for Propofol and Remifentanil (this model was choosen at anesthesiologist's discretion)",{"label":13,"type":10,"description":14,"interventionNames":10},"Minto TCI","Patients who received general anesthesia with Eleveld TCI model for Propofol and Minto TCI for Remifentanil (this model was choosen at anesthesiologist's discretion)",[16],{"facility":17,"status":18,"city":19,"state":10,"zip":20,"country":21,"countryCode":22,"cosmosGeoPoint":23,"geoPoint":28,"contacts":29},"ULSS2 Marca Trevigiana","RECRUITING","Treviso","31100","Italy","IT",{"type":24,"coordinates":25},"Point",[26,27],12.2416,45.66673,{"lat":27,"lon":26},[30],{"name":31,"role":32,"phone":33,"phoneExt":10,"email":34},"Federico Linassi, MD","CONTACT","0422322440","federico.linassi@gmail.com",{"type":36,"investigatorFullName":37,"investigatorTitle":38,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Federico Linassi","MD, PhD, Principal investigator","100612877","minto-and-eleveld-remifentanil-target-controlled-infusion-tci-models-a-clinical-comparison-100612877",false,"NCT07259291","Minto and Eleveld Remifentanil Target Controlled Infusion (TCI) Models: a Clinical Comparison","Minto and Eleveld Remifentanil Target Controlled Infusion (TCI) Models: a Clinical Comparison Through qNOX and ANIi Reactions to Post-tetanic Count","TCI","Inclusion Criteria:\n\n* Undergo general anaesthesia with Targeted Controlled Infusion of Propofol (Eleveld model) and Remifentanil (Minto or Eleveld model)\n\nExclusion Criteria:\n\n* Neurological disease\n* Psychiatric disease","FEMALE","18 Years","80 Years",{"count":51,"type":52},100,"ESTIMATED","OBSERVATIONAL","Remifentanil is commonly used as an opioid during general anesthesia. In recent years, several pharmacokinetic\u002Fpharmacodynamic (PK\u002FPD) models for target-controlled infusion (TCI) have been developed, with the Eleveld model being one of the most recent and designed for broad applicability.\n\nThe aim of this study is to compare the Eleveld TCI model with the routinely used Minto model, in order to evaluate potential differences in the predicted effect-site concentrations (CeR) required to achieve equivalent analgesia levels, as measured by qNOX (CONOX monitor) and the Analgesia Nociception Index (ANI). Post-Tetanic Count (PTC) was also assessed during the maintenance phase to investigate possible differences in nociceptive index responses between the two TCI models.",[56,57,58],"Propofol","Anesthesia Brain Monitoring","Remifentanil",[60],"Analgesia monitoring","2026-06-05",{"date":63,"type":64},"2026-06-08","ACTUAL",{"date":66,"type":64},"2025-11-25",{"date":68,"type":52},"2026-12-30",{"name":5,"class":6},1]